用于治疗精神分裂症和重度抑郁症的布瑞哌唑：临床实践中药理学考虑的全面综述。
Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
机构信息
Edinoff, MD, Wu, MD, Odisho, MD, Louisiana State University Health Science Center Shreveport, Department of Psychiatry and Behavioral Medicine. Maxey, BS, Ren, BS, Leethy, BS, Louisiana State University Shreveport School of Medicine. Girma, MD, Alan D. Kaye, MD, PhD, Mychaskiw, DO, Louisiana State University Shreveport, Department of Anesthesiology, Shreveport, LA. Jessica S. Kaye, Adam M. Kaye, PharmD, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Department of Pharmacy Practice, Stockton, CA. Aaron J. Kaye, MD, Medical University of South Carolina, Department of Anesthesiology, Charleston, SC. Viswanath, MD, Louisiana State University Shreveport, Department of Anesthesiology, Shreveport, LA, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, Creighton University School of Medicine, Department of Anesthesiology, Omaha, NE, Valley Anesthesiology and Pain Consultants-Envision Physician Services, Phoenix, AZ. Urits, MD, Louisiana State University Shreveport, Department of Anesthesiology, Shreveport, LA, Southcoast Health, Southcoast Physicians Group Pain Medicine, Wareham, MA.
出版信息
Psychopharmacol Bull. 2021 Mar 16;51(2):69-95.
Mood and psychotic disorders are a group of illnesses that affect behavior and cognition. Schizophrenia is characterized by positive symptoms, such as delusions and hallucinations, as well as negative symptoms. Major depressive disorder (MDD) is a mood disorder that affects the patient's emotions, energy, and motivation. Brexpiprazole works as a partial agonist at serotonin 5-hydroxytryptamine1A and dopamine D2 receptors and an antagonist at serotonin 5-hydroxytryptamine2A. Schizophrenia and MDD have a wide range of risk factors, both biological and environmental. Third generation antipsychotics, which include brexpiprazole, are the latest group of drugs to reach the market, demonstrating efficacy and tolerability. Patients with acute schizophrenia have responded well to brexpiprazole. In this regard, in patients who have MDD plus anxiety symptoms, brexpiprazole can be effective as an adjunctive therapy and can reduce anxiety symptoms. In summary, brexpiprazole has proved to be an effective alternative to typical or first and second-generation atypical antipsychotics.
心境障碍和精神病性障碍是一组影响行为和认知的疾病。精神分裂症的特征是阳性症状，如妄想和幻觉，以及阴性症状。重度抑郁症（MDD）是一种心境障碍，影响患者的情绪、能量和动力。布瑞哌唑是 5-羟色胺 5-羟色胺 1A 和多巴胺 D2 受体的部分激动剂，是 5-羟色胺 5-羟色胺 2A 的拮抗剂。精神分裂症和 MDD 有广泛的风险因素，包括生物和环境因素。第三代抗精神病药，包括布瑞哌唑，是最新上市的一组药物，显示出疗效和耐受性。急性精神分裂症患者对布瑞哌唑反应良好。在这方面，对于伴有焦虑症状的 MDD 患者，布瑞哌唑可以作为辅助治疗有效，并且可以减轻焦虑症状。总之，布瑞哌唑已被证明是一种有效的替代典型或第一代和第二代非典型抗精神病药的选择。
Zotero 插件